Kenvue: Out Of Favor Then, Under Pressure Now [Seeking Alpha]
Kenvue Inc. (KVUE)
Company Research
Source: Seeking Alpha
Kenvue's shares traded lower on news that the Trump administration would release a report linking autism to acetaminophen use during pregnancy. Tylenol accounts for an estimated 12-15% of Kenvue's earnings. In October 2025, news broke that a group action lawsuit had been filed against Kenvue in the UK over claims that its talc-based products cause cancer. Proceeds from the sale of Kenvue were used to purchase a position in Zoetis Inc., a leading global provider of animal health products. MicroStockHub/iStock via Getty Images The following segment was excerpted from the Nomura Value Fund Q4 2025 Commentary. In October, we sold our position in Kenvue Inc. ( KVUE ), a consumer health company with globally recognizable brands such as Band-Aid, Listerine, Neutrogena, Tylenol, and Quick Insights Mounting headline risks, including Tylenol-autism claims and UK talc litigation, threatened to distract management and depress shares, outweighing turnaround and activist potential.
Show less
Read more
Impact Snapshot
Event Time:
KVUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KVUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KVUE alerts
High impacting Kenvue Inc. news events
Weekly update
A roundup of the hottest topics
KVUE
News
- Kenvue Declares Quarterly Cash DividendBusiness Wire
- Dermal Mycosis Market Research Report 2025-2026 & 2035, Competitive Analysis of Bayer, Kenvue, Karo Healthcare, Novartis, Glenmark Pharmaceuticals, Sun Pharma, Teva, and Sandoz [Yahoo! Finance]Yahoo! Finance
- Why Kenvue Inc. (KVUE) is One of the Best Cheap Stocks to Buy Under $20 [Yahoo! Finance]Yahoo! Finance
- Kenvue to Announce First Quarter 2026 Results on May 7, 2026Business Wire
- Kenvue (KVUE) had its price target lowered by Citigroup Inc. from $20.00 to $19.00. They now have a "neutral" rating on the stock.MarketBeat
KVUE
Earnings
- 2/17/26 - Beat
KVUE
Sec Filings
- 4/15/26 - Form 8-K
- 4/8/26 - Form ARS
- 4/8/26 - Form DEFA14A
- KVUE's page on the SEC website